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Microarrayed dog, cat, and horse allergens
show weak correlation between allergen-
specific IgE and IgG responsesTo the Editor:
The beneficial role of pet exposure and the development of
allergen-specific IgG antibodies induced by natural exposure is a
controversial issue. Increased levels of IgG antibodies to Fel d 1
were found to be associated with decreased sensitization in
children,1 and higher levels of IgG/IgG4 to mouse allergens were
found to be associated with decreased symptoms in laboratory
workers.2 However, another study reported that exposure and
high IgG levels to cat were not associated with a lower risk
of allergic respiratory symptoms.3 One possibility for this
discrepancy may be that allergen-specific IgE and IgG responses
are not synchronized and directed to the same allergens/epitopes.
To address this question and to define the most frequently
recognized animal allergens, we investigated allergen-specific
IgE and IgG responses by using microarrayed allergens.
Sera from patients with allergic symptoms clearly attributable
to cat exposure with and without concomitant allergy to dogs
and horses, from allergic patients without allergy to animals, and
from subjects without allergy were studied (see Table E1 in this
article’s Online Repository at www.jacionline.org). By using the
ImmunoCAP ISAC technology (Thermo Fisher, Uppsala, Sweden,
and Vienna, Austria), customized allergen microarrays containing
in addition to Can f 1, Can f 2, Can f 3, and Can f 5, 2 recently
described dog allergens, that is, Can f 4 and Can f 6, were
prepared.4 Fig E1 in this article’s Online Repository at www.
jacionline.org shows that recombinant Can f 4 (rCan f 4)
and rCan f 6 exhibit correct molecular weight, are pure, and are
folded. In addition, the chip also contained the cat allergens rFel
d 1, natural Fel d 2 (nFel d 2), and rFel d 4 and the horse
allergens rEqu c 1 and nEqu c 3. The simultaneous analysis of
IgE and IgG responses toward 11 animal allergens showed that
allergen-specific IgE and IgG responses were only poorly
correlated (Fig 1 and Table I). High correlation between IgE and
IgG antibodies was found only for Can f 4 (r 5 0.728; P < .001),
moderate correlations were observed for Can f 1 (r 5 0.581;
P < .05), Can f 2 (r 5 0.504; P < .05), and Equ c 3 (r 5 0.550;
P < .05), and no correlations were observed for the other animal-
derived allergens (Table I). Often, animal-allergic patientswithout IgE reactivity to certain allergen componentsmounted pro-
nounced IgG responses toward these allergens (Fig 1 and Table I).
Furthermore, allergic patients without animal allergy and nonal-
lergic individuals exhibited specific IgG antibody responses toward
animal allergens similar to those of animal-allergic patients (Fig 1).
Almost for each tested allergen (ie,Can f 2,Can f 3,Can f 4,Can f 5,
Can f 6, Fel d 1, andFel d 2),we foundallergic patientswho showed
selective IgE reactivity without detectable IgG antibodies (Fig 1
and Table I). Similar finding were made for house dust mite
allergens (see Fig E2 in this article’s Online Repository at www.
jacionline.org). Moderate correlation between IgE and IgG was
observed for only 2 of the 12 allergens, namely, Der p 2 and Der p
23 (r5 0.560,P< .05, and r5 0.545,P< .05, respectively; Fig E2).
In the case of a strictly sequential class-switch from
allergen-specific IgG to IgE production, one would expect a
good correlation between IgE and IgG responses but our results
provide evidence for a direct switch from IgM to allergen-specific
IgE without intermediate IgG response. Our results therefore may
explain why natural allergen exposure does not always induce
protective IgG responses leading to immunological tolerance as
has been suggested for cat allergy because IgG is directed to other
allergens/epitopes than is IgE.
In the group of dog-allergic patients (Table E1: patients 1-17),
the frequencies of IgE reactivity to the individual dog allergens
were as follows: Can f 1, 13 of 17 (76%); Can f 3, 10 of 17
(59%); Can f 5, 12 of 17 (71%); Can f 4, 10 of 17 (59%); Can f
2, 6 of 17 (35%), and Can f 6, 4 of 17 (23%) (Fig 1). In the group
of cat-allergic patients, the frequencies of IgE reactivity to cat
allergens (Table E1: patients 1-24) were as follows: Fel d 1, 24
of 24 (100%); Fel d 4, 15 of 24 (63%); and Fel d 2, 13 of 24
(54%). Using Equ c 1 and Equ c 3, only 6 of the 11 patients
(Table E1: patients 1-4, 9-11, 15, 16, 21, and 23) reporting
symptoms on contact with horses were identified, indicating that
additional horse allergen components were needed. Each of the
patients who had reported allergic symptoms on contact with
dogs showed IgE reactivity to at least 1 of the microarrayed dog
allergens and each of the patients who had reported symptoms
on contact with cats reacted with at least 1 of the cat allergens pre-
sent on the chip, indicating high sensitivity of the microarray for
diagnosing cat and dog allergy. No IgE binding to microarrayed
animal allergen components was detected in sera from nonallergic
subjects or allergic patients with house dust mite and/or pollen al-
lergy without animal allergy, indicating specificity of the microar-
ray. Interestingly, IgE reactivity to dog and cat allergen extracts
was found by ImmunoCAP measurements in allergic patients
without clinical animal allergy (Table E1, patients 25 and 26).
Our findings need to be confirmed in a larger population of patients
to identify the most relevant animal allergens. Nevertheless, the
chip should be useful for studying dog and cat allergen-specific
IgE responses to follow the evolution of IgE responses in birth co-
horts5 and in populations from various countries.
Fig E3 in this article’s Online Repository at www.jacionline.
org shows that there is a sequence identity of 67% and 57%
between the lipocalins Fel d 4 and Equ c 1 with the dog allergen
Can f 6, respectively, and a very high sequence identity of
more than 74% between the albumins from dog, cat, and horse
(ie, Can f 3, Fel d 2, and Equ c 3). Dog, cat, and horse lipocalin
allergens Can f 6, Fel d 4, and Equ c 1, which had previously
been reported to be cross-reactive at the IgE level,6 showed a
significant correlation of IgE reactivities between Fel d 4 and
Equ c 1 (r5 0.557, P < .005; see Table E2 in this article’s Online
              rCan f 1             rCan f 2             rCan f 4                rCan f 5              rFel d 1               nCan f 3             nFel d 2               nEqu c 3              rCan f 6           rFel d 4               rEqu c 1
group patient IgE IgG IgE IgG IgE IgG IgE IgG IgE IgG IgE IgG IgE IgG IgE IgG IgE IgG IgE IgG IgE IgG
1 1.04 37.48 0.00 0.00 1.13 31.67 0.00 1.03 1.99 21.23 0.00 1.20 0.00 1.46 0.00 0.91 0.00 3.74 0.00 3.60 0.00 1.30 IgE reactivity
2 37.31 11.38 0.00 0.00 19.28 2.50 4.58 0.98 29.67 55.75 66.15 63.88 78.38 96.08 26.67 44.52 2.39 1.64 16.42 17.38 0.79 5.50 negative
3 5.21 0.77 0.00 0.00 1.42 0.47 0.00 0.40 5.33 2.79 0.00 4.55 0.17 2.80 0.00 0.97 0.00 1.75 0.17 4.32 0.00 1.14 0.1-0.9
4 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.46 5.10 2.07 4.27 3.53 2.93 3.57 0.00 0.00 0.00 3.46 1.69 36.95 2.95 1.77 1-14.9
DCA 5 9.01 8.16 2.06 0.00 5.93 5.77 0.41 0.84 7.69 3.62 2.64 0.00 0.00 0.26 0.00 0.24 0.00 0.82 3.42 4.19 4.50 1.91 >15
6 9.72 9.76 9.85 10.69 2.00 3.20 3.52 0.94 15.10 4.19 0.77 2.06 0.58 1.65 0.00 10.93 0.00 0.00 3.17 8.48 0.28 3.86
7 9.33 7.85 5.25 2.66 0.00 0.00 0.14 2.59 6.83 10.71 1.57 3.79 2.23 1.58 0.00 0.60 0.00 1.51 0.58 4.35 0.00 0.00 IgG reactivity
8 2.64 66.50 0.00 0.81 4.71 59.01 1.08 9.62 1.03 35.00 0.00 10.09 0.00 18.43 0.00 1.74 0.00 14.02 0.49 34.26 0.00 7.13 negative
9 0.00 1.97 0.00 4.66 0.00 0.00 3.62 11.46 14.14 7.49 0.00 0.00 0.00 0.00 0.00 0.00 0.31 5.58 8.90 22.17 0.56 9.93 0.1-0.9
10 9.60 11.16 15.24 10.41 0.00 0.98 7.89 4.08 10.28 9.61 0.32 0.00 0.15 0.00 0.00 0.00 0.00 0.00 1.89 6.33 0.00 0.00 1-14.9
11 2.67 5.50 0.00 0.00 0.00 0.26 0.22 1.93 14.05 2.34 0.00 2.21 0.00 1.99 0.00 0.90 0.00 0.93 1.75 2.97 0.00 6.40 >15
12 21.50 6.65 28.58 9.70 74.57 7.85 8.39 11.10 30.94 4.51 71.48 8.70 25.59 3.26 19.66 4.74 4.27 0.00 0.23 8.79 0.00 6.87
13 2.35 2.70 0.00 0.00 0.00 0.42 0.50 0.83 1.45 0.91 0.00 0.59 0.00 0.00 0.00 0.48 0.32 1.26 0.16 1.92 0.14 3.17
14 0.00 16.52 0.00 8.95 0.18 0.00 2.01 1.20 4.19 1.38 0.19 9.95 0.23 7.42 0.00 2.46 0.00 2.65 0.00 5.59 0.00 5.45
15 2.07 7.61 1.62 0.00 0.87 4.67 0.60 15.68 2.03 4.36 2.61 29.54 1.20 24.27 0.38 12.37 0.00 0.00 0.56 14.68 0.00 10.19
16 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 10.15 2.30 5.69 1.56 4.62 1.26 0.12 0.95 0.00 0.86 0.00 7.91 0.00 0.00
17 0.78 5.34 0.00 7.89 7.72 77.24 0.00 1.70 5.41 27.33 0.00 40.43 0.00 37.76 0.00 36.80 0.00 15.02 2.66 8.08 0.00 2.69
18 0.00 0.00 0.00 0.00 0.00 0.00 5.20 44.84 5.98 39.06 0.00 0.00 0.33 0.00 0.00 0.00 0.00 0.00 0.00 7.79 0.00 1.09
19 2.97 47.54 1.14 24.17 12.81 34.41 1.09 0.00 1.78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.54 0.00 0.00 31.21 0.00 15.63
20 0.00 2.13 0.00 2.98 0.00 3.25 0.00 1.38 27.45 8.79 0.00 0.57 0.60 0.71 0.00 1.36 0.00 1.21 0.00 18.36 0.00 6.36
CA 21 0.24 3.45 0.00 0.00 0.00 0.00 0.00 2.77 0.41 23.85 0.96 12.85 1.27 20.46 0.61 3.51 0.00 4.17 3.98 11.57 0.00 4.22
22 0.00 1.55 0.00 0.00 0.00 0.55 0.00 1.47 2.13 7.94 0.00 0.88 0.00 0.80 0.00 0.68 0.00 3.52 0.00 17.19 0.00 6.96
23 0.60 6.76 0.00 0.00 0.00 0.00 1.66 1.60 4.74 2.51 0.00 4.99 0.00 4.88 0.00 0.00 0.00 1.33 0.00 5.15 0.00 1.28
24 0.00 4.50 0.00 1.90 0.00 3.19 0.00 5.41 2.25 7.51 0.00 4.06 0.00 1.44 0.00 1.56 0.00 3.38 0.00 5.85 0.00 2.88
25 0.00 0.00 0.00 2.37 0.00 0.00 0.00 1.15 0.00 5.23 0.00 46.94 0.00 60.36 0.00 7.38 0.00 1.66 0.00 5.17 0.00 3.18
OA 26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.97 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
27 0.00 1.35 0.00 2.52 0.00 0.50 0.00 0.82 0.00 2.14 0.00 0.79 0.00 1.07 0.00 1.61 0.00 1.75 0.00 15.81 0.00 6.17
28 0.00 0.33 0.00 0.00 0.00 0.00 0.00 1.50 0.00 0.32 0.00 1.31 0.00 1.22 0.00 0.00 0.00 0.96 0.00 5.67 0.00 3.29
29 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.55 0.00 2.45 0.00 4.66 0.00 0.91 0.00 1.00 0.00 3.25 0.00 2.11
30 0.00 0.36 0.00 0.00 0.00 0.00 0.00 0.00 0.00 7.98 0.00 0.00 0.00 0.00 0.00 0.36 0.00 1.80 0.00 2.73 0.00 3.56
NA 31 0.00 0.63 0.00 0.00 0.00 0.29 0.00 0.00 0.00 0.46 0.00 0.33 0.00 0.47 0.00 1.01 0.00 2.44 0.00 9.19 0.00 5.20
32 0.00 0.63 0.00 0.67 0.00 0.00 0.00 0.45 0.00 0.71 0.00 1.56 0.00 0.89 0.00 0.45 0.00 1.82 0.00 12.97 0.00 4.21
33 0.00 0.81 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.62 0.00 0.00 0.00 0.00 0.00 2.25 0.00 1.23 0.00 2.77
34 0.00 0.45 0.00 0.68 0.00 0.00 0.00 0.56 0.00 0.92 0.00 0.28 0.00 0.35 0.00 0.47 0.00 0.96 0.00 4.63 0.00 1.73
35 0.00 0.34 0.00 0.00 0.00 0.00 0.00 0.79 0.00 0.69 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.61 0.00 3.76 0.00 2.08
36 0.00 3.89 0.00 2.93 0.00 0.92 0.00 0.56 0.00 2.29 0.00 1.78 0.00 1.54 0.00 3.73 0.00 4.52 0.00 27.80 0.00 5.23
FIG 1. Heat map of patients’ IgE and IgG reactivity. IgE and IgG levels (inserts show color codes for the levels) specific for microarrayed dog (Can f 1-6), cat (Fel d 1,
Fel d 2, and Fel d 4), and horse (Equ c 1 and Equ c 3) allergens are displayed for 4 groups of subjects (DCA, patients with symptoms to dog and/or cat; CA, cat-allergic
patients; OA, allergic patients without allergy to animals; NA, nonallergic subjects). n, Natural; r, recombinant.
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TABLE I. Correlations between allergen-specific IgE and IgG levels of animal-derived allergens
IgG IgE Can f 1 Can f 2 Can f 3 Can f 4 Can f 5 Can f 6 Fel d 1 Fel d 2 Fel d 4 Equ c 1 Equ c 3
Can f 1 r 5 0.581*
P 5 .003
Can f 2 r 5 0.504
P 5 .01
Can f 3 r 5 0.281
P > .05
Can f 4 r 5 0.728*
P < .001
Can f 5 r 5 0.304
P > .05
Can f 6 r 5 20.168
P > .05
Fel d 1 r 5 0.100
P > .05
Fel d 2 r 5 0.337
P > .05
Fel d 4 r 5 0.154
P > .05
Equ c 1 r 5 0.048
P > .05
Equ c 3 r 5 0.550*
P < .005
*P values less than .005 were considered highly significant.
P values less than .05 were considered significant.
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920 LETTERS TO THE EDITORRepository at www.jacionline.org) but not between the 2 other
pairs of lipocalins (Can f 6: Fel d 4, r 5 0.163, P > .05; Can f
6: Equ c 1, r 5 0.325, P > .05). The weak IgE cross-reactivity
among the lipocalin allergens was also evident by the fact that
many patients displayed selective IgE reactivity to members
of this allergen family. For example, 9 patients showed
selective IgE reactivity to Fel d 4 but not to Equ c 1 and 11 patients
showed IgE reactivity to Fel d 4 but not to Can f 6 (Fig 1; see Table
E2).
Significant correlations in IgE reactivity were found between
serum albumins from dog, cat, and horse (Can f 3 vs Fel d 2,
r5 0.788,P< .001; Can f 3 vs Equ c 3, r5 0.690,P< .001; Equ c 3
vsFel d 2, r50.684,P<.001;TableE2).However, for the albumins
also, several patients were found with selective IgE reactivities
toward certain albumins (Fig 1 and Fig E2). The poor associations
of IgE reactivities between the lipocalins and albuminsmay also be
due to IgG competing with IgE for chip-bound allergens.
In summary, we report a microarray containing 11 purified
recombinant and natural allergens from dog, cat, and horse and its
usefulness for the diagnosis of IgE sensitization to dogs and cats
and the parallel analysis of allergen-specific IgG responses. The
microarray not only allowed sensitive and specific detection of
dog and cat allergen-specific IgE but also identified allergens that
may be relevant components of vaccines and allowed to reveal
species-specific sensitizations due to limited cross-reactivity of
the allergen components. Furthermore, we discovered an inter-
esting dissociation of allergen-specific IgE and IgG responses that
indicates that nonsequential class-switch mechanisms are
operative in animal allergy and may explain why naturally
occurring allergen-specific IgG is not always protective.
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Outcomes after cessation of mepolizumab
therapy in severe eosinophilic asthma:
A 12-month follow-up analysisTo the Editor:
Treatment with the neutralizing monoclonal anti–IL-5
antibody mepolizumab for 12 months results in a significant
reduction in exacerbation frequency and eosinophilic airway
inflammation in subjects with refractory eosinophilic asthma.1,2
Little is known about the effects of withdrawal of anti–IL-5
treatment. A theoretical risk of ‘‘rebound’’ worsening of
eosinophilic airway inflammation associated with negative
outcomes has been suggested3 on the basis of in vitro observations
that anti–IL-5 therapy is associated with upregulation of IL-5
synthesis by TH2 cells, upregulation of IL-5R expression by
eosinophils, and persistence of preformed IL-5 in complex with
the drug for a variable period of time after cessation of therapy.4
As part of a follow-up analysis, subjects completing a
12-month study of mepolizumab in refractory asthma1 were
observed for 12 months with assessments every 3 months. The
aims of this period of observation were to examine the kinetics
of blood and sputum eosinophil counts, to examine the change
in clinical markers of asthma control following cessation of
therapy, and to investigate the temporal relationship between
the change in biological and clinical control of disease. In
addition, radiological markers of airway remodeling characte-
rized by using helical thin-section computed tomography (CT)
during the trial were assessed at the beginning and end of the
12-month follow-up period.
This was an unblinded, prospective, observational study.
Systematic follow-up at 3-month intervals was maintained for
study subjects in our Refractory Asthma Clinic for 12months (see
Fig E1 in this article’s Online Repository at www.jacionline.org).
All subjects provided written informed consent for the clinical
trial, for recording analysis and reporting of data during the
observation period and for an additional CT scan performed at
the end of the observation period. The clinical trial was supported
by an unrestricted grant from GlaxoSmithKline.
The final visit for treatment with either mepolizumab or
placebo was assigned as the baseline visit for the follow-up
analysis. This was the final visit during the study at which blood
and sputum samples were collected. The 12-month follow-up
period was calculated from this time point. All subjects received a
2-week course of oral prednisolone 30 mg once daily 2 weeks
after this visit to optimize pulmonary function before a CT scan as
part of the trial protocol. Details of the assessment and analysis
are available in this article’s Online Repository at www.
jacionline.org.Fifty-six subjects (27 assigned to mepolizumab) completed the
original study. Characteristics of these subjects at the baseline
visit for follow-up are summarized in Table E1 in this article’s
Online Repository at www.jacionline.org, and subject disposition
is described in the Online Repository. The frequency of severe
exacerbations in the 12-month follow-up observational period
was 3.1 per subject in those previously treated with placebo
and 3.9 per subject in those previously treated with mepolizu-
mab (rate ratio, 1.25; 95% CI, 0.71-1.91; P 5 .54). There
was a significant increase in the overall frequency of severe exac-
erbations from 0.56/patient at 0 to 3 months to 1.2/patient (P 5
.007) at 3 to 6 months for subjects who were treated with
mepolizumab (rate ratio, 2.11; 95% CI, 1.76-2.54; P < .001) but
not placebo (Fig 1). Changes to drug therapy are outlined in the
Online Repository.
Significant between-visit increases in the blood eosinophil
count were observed at 0 to 3 months (P< .001) and 3 to 6 months
(P 5 .004; Fig 1; Table I) after stopping mepolizumab but
not placebo. For the sputum eosinophil count, a significant
rise occurred at 0 to 3 months (P 5 .03) but not thereafter
(Fig 1; Table I). The Juniper Asthma Control Questionnaire
(JACQ) rose by a mean of 0.59 points over the 12 months after
the final treatment visit for subjects who received mepolizumab
but not placebo (Fig 1; Table I). Most of the between-group differ-
ence could be attributable to a significant fall in JACQ (P5 .049)
occurring in the placebo group for the interval 9 to 12months after
the final treatment visit of the study (Fig 1). No significant differ-
ences in postbronchodilator FEV1 or fraction of exhaled nitric
oxide were seen (Fig 1; Table I).
A significant within-group increase in airway wall area per unit
body surface area was identified in both groups (mean difference
[95% CI]: placebo group, 1.2 mm2/m2 [0.1-2.2], P 5 .03;
mepolizumab group, 1.0 mm2/m2 [0.2-1.8], P5 .01). Participants
who received mepolizumab had a significant increase in the
total area of their measured airway (mean difference [95% CI],
1.4 mm2/m2 [0.2-2.6], P 5 .03]) (see Table E1).
Our study is the first to report changes that occur after stopping
mepolizumab therapy in a study population likely to be relevant to
the population treated with this agent. Cessation of mepolizumab
was associated with a rise in the blood eosinophil count beginning
soon after stopping therapy and continuing to baseline over
6 months. The frequency of severe exacerbations increased
significantly after stopping mepolizumab, and 12 months after
stopping mepolizumab, exacerbation frequency was not
significantly different between subjects of the 2 study groups.
The rise in exacerbations at 3 to 6 months after stopping
mepolizumab was preceded by a rise in sputum and blood
eosinophils, supporting suggestions that these events are related
but have different time courses.5-8
The finding of increased asthma symptoms following
cessation of mepolizumab was unexpected because symptoms
were not modified significantly during the treatment period.1
However, mean symptom scores for subjects receiving mepoli-
zumab were lower than for subjects in the placebo group at the
end of the treatment phase of the study. The rise in symptoms
after stopping therapy may therefore in part represent regres-
sion to the mean. An increasing frequency of severe exacerba-
tions will have also contributed to higher symptom scores at
each routine visit. We consider it unlikely that the increase
in symptoms after mepolizumab withdrawal was due to a
rebound phenomenon because it was not associated with
METHODS
Patients’ sera
Sera from 24 adult animal-allergic patients suffering from rhinitis,
conjunctivitis, asthma, urticaria, and/or atopic dermatitis were analyzed. All
patients had reported allergic symptoms attributable to contact with cat
(patients 1-24, Table E1), and 1 subset exhibited allergic symptoms to cat and
additionally to dog and/or horse (patients 1-17, Table E1). As controls, sera
from 3 subjects with allergy to pollen or/and house dust mite but without
allergy to animal dander and from 9 nonallergic subjects were analyzed.
Control subjects were exposed to cats and dogs. All subjects were from
Austria. The anonymized analysis of sera was approved by the ethics
committee of the Medical University of Vienna, and subjects had signed
approved consent forms. For each patient, a detailed case history summarizing
allergic symptoms to animals and other allergen sources was established.
In particular, patients were asked in detail about the occurrence, type, and
intensity of allergic symptoms on contact with animals (ie, dog, cat, horse,
rabbit, mice, guinea pig, cow, and sheep) (Table E1). None of the
animal-allergic patients had received allergen-specific immunotherapy for
animal allergies. Symptoms on contact with animals were recorded, and
symptoms on contact with other allergen sources were also noted
(Table E1). Animal-allergic patients were frequently cosensitized to house
dust mites and grass/tree pollen. Each serum was tested regarding total IgE
levels and for IgE reactivity to natural dog dander (e5) and cat dander (e1)
allergen extracts as determined by the ImmunoCAP System (Thermo Fisher
Scientific/Phadia, Uppsala, Sweden). Table E1 summarizes the demographic,
clinical, and serologic characteristics of the patients.
Expression and purification of recombinant dog
allergens
Genes coding for the mature forms of Can f 4 (ACY38525.1) and Can f 6
(E2QYS2) was synthesized by using PCR-based assembly of oligonucleotides
(GenScript, Piscataway, NJ) and inserted into theNdeI/EcoRI sites of pET-27b
(Novagen, Darmstadt, Germany). Both genes contained sequences coding for
a hexahistidine tag at the C terminus of the protein, and the gene sequences
were optimized for Escherichia coli expression. The DNA sequences were
confirmed bymeans of restriction enzyme analysis with corresponding restric-
tion enzymes (Roche, Mannheim, Germany) and by automated sequencing of
both DNA strands. E coliBL 21 DE3 (Stratagene, La Jolla, Calif) transformed
with pET 27b-Can f 4 and pET 27b-Can f 6 were grown at 378C for approxi-
mately 10 hours in a GFL 3033 incubator (GFL, Burgwedel, Germany) in
Luria Bertani medium containing kanamycin (30 mg/mL) until a cell density
(OD600nm) of 0.5 for Can f 4 and 0.2 for Can f 6 was reached. Protein expres-
sion was induced by adding 0.5 mmol/L isopropyl-b-thiogalactopyranoside
(Calbiochem,Merck, Darmstadt, Germany). Cells were harvested by centrifu-
gation at 6000g for 10 minutes. rCan f 4 was purified under native conditions.
For this purpose, cell pellets were lysed with an Ultra-Turrax (Janke &
Kunkel-IKA Labortechnik, Staufen, Germany) in lysis buffer (50 mM
NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8). rCan f 6 was purified
under denaturing conditions. In this case, cell pellets were lysed in lysis buffer
A (100 mM NaH2PO4, 10 mM Tris-HCl, 8 mol/L Urea, pH 8). Both
recombinant proteins were purified by Ni21 metal-ion affinity chromato-
graphy according to the manufacturer’s protocol (Qiagen, Hilden, Germany).
Finally, purified Can f 4 was dialysed against PBS (pH 9) and rCan 6 was
refolded by extensive dialysis against 10 mM NaH2PO4 (pH 7.5). The purity
of the recombinant proteins was analyzed by using SDS-PAGEE1 and
Coomassie blue staining under reducing and nonreducing conditions.
The molecular masses were determined by matrix-assisted laser desorption/
ionization time-of-flight mass spectrometry (Bruker, Billerica, Mass), and
the protein concentration was determined by Micro-BCA Protein Assay Kit
(Pierce, Rockford, Ill).
Circular dichroism analysis
The circular dichroism spectra of purified recombinant rCan f 4 and rCan f
6 were measured on a JASCO J-810 spectropolarimeter (Tokyo, Japan).
Measurements were performed at protein concentrations of 0.1 mg/mL in a
rectangular quartz cuvette with a path length of 0.2 cm. Spectra were recorded
from 190 to 260 nm with a resolution of 0.5 nm at a scan speed of 50 nm/min
and were derived from 3 scans. Final spectra were corrected by subtracting the
baseline spectra obtained with the buffers alone. Results are displayed as the
mean residue ellipticities (Q) at given wavelengths. The secondary structure
contents of the proteins were calculated with the secondary structure
estimation programs CDSSTR and CONTIN.E2
Extended ISAC microarray
The animal allergen spectrum of ImmunoCAP ISAC (Thermo Fisher,
Uppsala, Sweden) was expanded regarding rCan f 4 and rCan f 6. Allergens
were spotted in triplicates, and IgE standards were added as for ImmunoCAP
ISAC (Thermofisher). The animal allergen repertoire of the chip comprised
dog allergens (rCan f 1, rCan f 2, nCan f 3, rCan f 4, rCan f 5, and rCan f 6), cat
allergens (rFel d 1, nFel d 2, and rFel d 4), and horse allergens (rEqu c 1 and
nEqu c 3).E3 Quality controls were performedwith IgE and IgG standards with
established IgE and IgG reactivity to allergen components on the chip. For IgE
detection, 30 mL of serum, or for IgG detection 30 mL of a 1:50 dilution of
serum, was added to the microarray and incubated for 120 minutes, followed
by washing and incubation with fluorescence-labeled anti-IgE or anti-IgG
antibodies (Thermo Fisher), respectively, for 30 minutes. Then, chips were
washed, dried, and analyzed with a Laser Scan Confocal microarray
reader (LuxScan 10K/A; Capital-Bio, Beijing, China) and evaluated with
Phadia Microarray Image Analysis software. Antibody levels are given as
semiquantitative ISAC Standardized Units (ISUs) with a cutoff of 0.1 ISU.
The allergen-specific antibody levels were classified as low (0.1-1 ISUs),
moderate to high (>1-15 ISUs), or very high (>15 ISUs).
Statistical analysis
For all statistical analyses, the statistical ProgramSPSS (2008, version 16.0;
SPSS, Inc, Chicago, Ill) was used. P values of less than .05 were considered
significant. Correlations between variables were analyzed by using the
Spearman-Rho test.
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FIG E1. Biochemical and structural characterization of rCan f 4 and rCan f 6. A, Coomassie brilliant
blue–stained SDS-PAGE containing rCan f 4 and rCan f 6 under reducing and nonreducing conditions.
Molecular weights (M) are indicated at the left margins. B, Circular dichroism spectra of rCan f 4 and
rCan f 6. The mean residue ellipticities (Q) (y-axes) are shown at given wavelengths (x-axes).
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              Der p 1            Der p 2              Der p 4                Der p 5               Der p 7               Der p 10             Der p 11             Der p 14               Der p 15           Der p 18             Der p 21           Der p 23
group patient IgE IgG IgE IgG IgE IgG IgE IgG IgE IgG IgE IgG IgE IgG IgE IgG IgE IgG IgE IgG IgE IgG IgE IgG
1 2.30 6.11 8.20 9.66 0.00 1.88 1.03 2.18 0.62 1.65 0.00 0.90 0.00 6.31 0.00 6.40 0.00 1.96 0.00 4.92 1.42 4.64 8.92 6.76 IgE reactivity
2 0.00 3.02 3.43 1.02 0.00 3.81 0.00 4.19 0.00 1.09 0.00 0.00 0.00 2.63 0.00 2.34 0.00 1.71 0.00 1.93 0.00 3.23 0.00 6.42 negative
3 0.85 2.62 0.69 0.70 0.00 0.66 0.00 0.86 0.00 1.01 0.00 0.78 0.00 2.22 0.00 2.28 0.00 1.89 0.00 2.53 0.00 4.75 0.90 1.07 0.1-0.9
4 0.00 1.97 0.00 0.00 0.00 8.00 0.00 2.22 0.00 7.47 0.00 0.00 0.00 1.82 0.00 5.96 0.00 2.76 0.00 9.26 0.00 0.00 0.00 0.00 1-14.9
DCA 5 0.00 0.71 8.70 8.80 0.00 1.26 0.00 0.72 0.00 1.24 0.00 0.71 0.00 1.93 0.00 1.92 0.00 1.98 0.00 2.94 0.00 1.10 13.24 3.71 >15
6 1.05 4.35 10.20 4.57 0.00 4.76 0.00 1.50 0.17 6.35 0.93 0.00 0.25 3.62 0.00 4.60 0.00 1.75 0.00 5.39 0.00 1.52 7.52 5.08
7 2.23 1.55 5.65 2.71 0.00 6.94 0.00 1.85 0.00 1.09 0.00 0.70 0.12 2.07 0.00 1.88 0.00 1.86 0.00 5.24 0.00 0.00 5.36 4.53 IgG reactivity
8 0.00 4.35 0.90 2.72 0.00 6.46 0.00 3.59 0.00 20.40 0.00 0.65 0.00 2.99 0.00 3.29 0.00 3.13 0.00 9.80 0.00 3.02 1.64 2.85 negative
9 0.00 5.54 0.00 1.09 0.00 0.00 0.00 1.33 0.00 1.50 0.00 0.00 0.00 4.04 0.00 7.23 0.00 10.67 0.00 7.60 0.00 3.61 0.00 2.50 0.1-0.9
10 0.00 0.00 0.00 1.73 0.00 0.00 0.00 0.00 0.00 0.81 0.00 0.00 0.00 1.29 0.00 1.12 0.00 2.18 0.00 1.64 0.00 0.00 0.00 2.04 1-14.9
11 0.00 1.22 0.00 0.56 0.00 0.76 0.00 0.84 0.00 1.14 0.00 0.47 0.00 2.24 0.00 2.05 0.00 2.52 0.00 3.22 0.00 1.91 0.00 2.38 >15
12 0.00 2.55 1.63 0.00 0.00 0.00 0.00 0.98 0.25 8.53 0.00 0.00 0.00 1.63 0.00 3.26 0.00 2.99 0.00 7.13 0.00 1.78 0.25 3.26
13 0.00 2.27 0.55 1.03 0.00 1.34 0.00 3.44 0.00 1.25 0.00 0.83 0.00 2.21 0.00 1.83 0.00 1.94 0.00 4.17 0.14 0.00 0.54 2.94
14 0.00 4.15 5.38 0.00 0.00 0.00 0.00 2.30 0.00 1.07 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.12 0.00 3.36 0.00 0.00 0.00 1.16
15 0.00 3.94 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.02 0.00 14.40 0.00 0.00 0.00 12.23 0.00 0.00 0.00 0.00
16 0.00 1.33 0.00 2.43 0.00 1.10 0.00 0.39 0.00 0.65 0.00 0.00 0.00 0.88 0.00 0.85 0.00 1.81 0.00 1.69 0.00 0.00 0.00 2.07
17 0.00 2.72 0.00 0.65 0.00 1.24 0.00 4.84 0.11 1.23 0.00 1.00 0.00 5.54 0.00 6.65 0.00 2.69 0.00 8.97 0.00 1.63 5.58 5.32
18 0.00 0.00 0.00 0.00 0.00 0.98 0.00 0.00 0.00 0.93 0.00 0.00 0.00 1.44 0.00 1.76 0.00 0.00 0.00 3.42 0.00 0.92 0.00 2.12
19 21.65 0.00 52.60 0.00 0.71 0.00 0.86 0.00 0.31 0.00 0.00 0.00 0.62 0.00 0.00 0.00 0.41 0.00 0.31 0.00 0.17 0.00 0.00 0.00
20 0.00 5.71 0.00 2.15 0.00 8.94 0.00 2.93 0.00 3.18 0.00 1.52 0.00 8.19 0.00 8.03 0.00 4.50 0.00 16.19 0.00 7.14 0.00 7.82
CA 21 0.00 2.06 0.00 0.84 0.00 1.02 0.00 5.77 0.00 3.13 0.00 0.99 0.00 4.04 0.00 3.31 0.00 1.71 0.00 4.52 0.00 0.00 0.00 2.39
22 0.00 5.90 19.74 10.92 0.00 4.00 0.27 3.19 0.14 1.90 0.59 0.91 0.00 2.17 0.00 2.28 0.00 2.79 0.00 6.14 0.00 1.98 9.27 3.33
23 12.61 4.09 17.59 2.99 0.35 3.33 7.08 1.05 0.76 1.67 0.00 0.00 0.00 2.30 0.00 3.58 0.00 1.65 0.00 2.78 7.68 3.52 33.95 3.73
24 3.39 13.46 12.22 11.71 0.15 2.01 1.14 2.41 0.15 4.35 1.13 0.00 0.20 3.07 0.00 3.11 0.00 2.92 0.00 7.40 0.00 3.15 7.30 5.04
25 0.00 2.91 0.00 1.14 0.00 1.35 0.00 0.59 0.00 0.82 0.00 0.86 0.00 1.61 0.00 2.96 0.00 2.46 0.00 6.67 0.00 0.00 0.82 0.00
OA 26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
27 0.00 2.77 0.00 1.76 0.00 4.54 0.00 1.88 0.00 1.17 0.00 0.68 0.00 3.67 0.00 5.26 0.00 1.65 0.00 8.57 0.00 2.05 0.00 3.24
28 0.00 1.46 0.00 0.00 0.00 1.68 0.00 0.33 0.00 0.80 0.00 0.85 0.00 1.46 0.00 3.06 0.00 2.26 0.00 1.31 0.00 0.81 0.00 0.48
29 0.00 3.64 0.00 1.22 0.00 0.00 0.00 1.01 0.00 0.76 0.00 1.34 0.00 3.40 0.00 1.80 0.00 1.32 0.00 2.36 0.00 1.26 0.00 0.81
30 0.00 0.90 0.00 0.28 0.00 0.00 0.00 0.31 0.00 0.43 0.00 0.00 0.00 1.32 0.00 1.09 0.00 1.59 0.00 2.30 0.00 0.95 0.00 0.49
NA 31 0.00 1.97 0.00 0.61 0.00 5.70 0.00 5.31 0.00 1.07 0.00 0.84 0.00 2.31 0.00 1.43 0.00 2.31 0.00 7.85 0.00 0.65 0.00 2.02
32 0.00 3.37 0.00 0.45 0.00 2.89 0.00 0.91 0.00 3.03 0.00 0.00 0.00 2.36 0.00 1.02 0.00 0.00 0.00 7.44 0.00 0.99 0.00 1.50
33 0.00 1.55 0.00 0.84 0.00 0.00 0.00 5.05 0.00 0.00 0.00 0.00 0.00 2.56 0.00 2.66 0.00 0.79 0.00 6.77 0.00 0.73 0.00 1.38
34 0.00 0.47 0.00 0.58 0.00 0.47 0.00 0.53 0.00 2.12 0.00 0.27 0.00 1.28 0.00 1.26 0.00 1.03 0.00 3.05 0.00 0.86 0.00 1.87
35 0.00 1.63 0.00 0.00 0.00 0.00 0.00 0.37 0.00 0.59 0.00 0.00 0.00 0.40 0.00 1.35 0.00 1.29 0.00 1.92 0.00 0.00 0.00 0.39
36 0.00 2.21 0.00 2.62 0.00 7.92 0.00 11.83 0.00 6.09 0.00 4.64 0.00 10.34 0.00 7.86 0.00 3.58 0.00 17.40 0.00 9.79 0.00 4.00
FIG E2. Heat map of patients’ IgE and IgG reactivity. IgE and IgG levels (inserts show color codes for the levels) specific for microarrayed house dust mite allergens
(nDer p 1, rDer p 2, rDer p 4, rDer p 5, rDer p 7, rDer p 10, rDer p 11, rDer p 14, rDer p 15, rDer p 18, rDer p 21, and rDer p 23) are displayed for 4 groups of subjects
(DCA, patients with symptoms to dog and/or cat; CA, cat-allergic patients; OA, allergic patients without allergy to animals; NA, nonallergic subjects). n, Natural;
r, recombinant.
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FIG E3. Alignment of protein sequences of Can f 6, Fel d 4, and Equ c 1 (A) and Can f 3, Fel d 2, and Equ c 3
(B). Predicted signal sequences are marked in italics, and arrows mark the first amino acid of the mature
form of protein. Points indicate identical residues, and dashes indicate gaps. Sequence identities of
allergens to the mature Can f 6 and Can f 3 allergens are shown on the right side of the last lines of the
alignments.
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TABLE E1. Demographic, clinical, and serological characteristics of patients and control subjects
Allergy Subject Age (y) Sex
Symptoms on contact
with the following
animals
Symptoms
to animals Other allergies
Symptoms to other
allergen sources
Specific IgE level
(kUA/L)
Total IgE
level
(kU/L)Cat (e1) Dog (e5)
1 23 F Dog, cat, horse, rabbit AS, RH, tp, gp, hdm, nu AS, RH, CO, OAS 4.31 4.96 140
2 42 F Dog, cat, horse AS, RH, CO tp, gp, hdm, ve,
he, cm
AS, RH, CO, AD >100 66.70 >2000
3 26 F Dog, cat, horse, rodents AS, RH, CO, U tp, gp, hdm, fi, nu AS, RH, CO >100 14.60 570
4 36 F Dog, cat, horse AS, U gp, hdm RH 15.70 6.27 218
DCA 5 29 M Dog, cat AS, RH, CO tp, gp, hdm AS, RH, CO, AD 19.70 63.00 >2000
6 34 F Dog, cat AS, CO, AD tp, gp, hdm AS, RH, CO, AD 75.60 78.10 >2000
7 26 M Dog, cat, guinea pig,
sheep
CO, AD tp, gp, hdm, he, nu AS, RH, CO, AD,
OAS
19.30 4.47 >2000
8 23 M Dog, cat AS, RH, CO tp, gp, hdm, fr AS, RH, CO, OAS 10.00 16.40 316
9 27 M Dog, cat, horse, rabbit,
guinea pig
RH, CO tp, me RH 31.30 4.44 129
10 26 M Dog, cat, horse, rabbit,
guinea pig
AS, AD tp, fr, nu RH, CO, AD, OAS 52.70 12.70 >5000
11 37 M Dog, cat, horse AS, RH, CO, AD tp, gp RH, CO 3.60 1.46 141
12 47 F Dog, cat AS, RH, AD tp, gp, hdm, fi AS, RH, AD, U >100 >100 1224
13 41 M Dog, cat RH tp, gp, ve RH, CO, OAS 0.55 1.81 44
14 30 F Dog, cat, guinea pig AS, RH, CO tp, gp, hdm, mo, me,
fi, nu
AS, RH, CO, OAS 3.55 5.20 997
15 47 M Dog, cat, horse AS, RH, CO, U tp, gp AS, RH, CO 13.20 20.10 420
16 26 M Dog, cat, horse, guinea
pig
RH, CO tp, gp RH, CO 62.20 6.00 798
17 27 M Dog, cat, guinea pig AS, RH tp, gp, hdm, fr AS, RH, OAS 61.00 20.80 938
18 27 M Cat AS gp, me AS >100 73.20 2706
19 19 M Cat AS gp, hdm AS 4.97 9.97 1771
20 36 F Cat AS, RH, CO wf RH >100 17.10 1035
CA 21 29 F Cat, horse AS, RH, CO me U 11.30 2.46 101
22 29 F Cat RH, CO tp, gp, hdm, fr AS, RH, CO, OAS 3.51 0.75 490
23 27 F Cat, horse RH, CO tp, gp, hdm, fr RH, CO, OAS 3.47 2.89 >5000
24 26 M Cat RH, CO gp, hdm AS, RH, CO 3.20 0.48 296
25 23 M 0 0 tp, gp, fr, ve RH, CO, OAS 0 0.78 410
OA 26 25 F 0 0 tp, gp, hdm, fr, nu RH, CO, OAS 0.41 0.68 130
27 34 M 0 0 gp RH, CO 0 0 45
28 29 F 0 0 0 0 0 0 31
29 29 M 0 0 0 0 0 0 44
30 27 F 0 0 0 0 0 0 8
NA 31 49 M 0 0 0 0 0 0 26
32 44 F 0 0 0 0 0 0 52
33 22 F 0 0 0 0 0 0 19
34 36 M 0 0 0 0 0 0 19
35 39 M 0 0 0 0 0 0 20
36 54 F 0 0 0 0 0 0 8
Demographic data and symptoms and sensitization to animal allergens are displayed for 24 dog/cat-allergic patients, 3 controls with allergy to pollen and/or house dust mite, and
9 nonallergic individuals. Total and allergen-specific IgE levels were measured by using ImmunoCAP and are displayed in kilo units/liter (kU/L) and kilo units of antigen/liter
(kUA/L), respectively. The cutoff value is 0.35 kUA/L.
AD, Atopic dermatitis; AS, asthma; CA, cat allergy; cm, cow’s milk; CO, conjunctivitis; DCA, dog or cat allergic; e1, cat dander extract; e5, dog dander extract; F, female; fi, fish;
fr, fruits; gp, grass pollen; hdm, house dust mite; he, hens egg; M, male; me, medicaments; mo, moulds; NA, not allergic; nu, nuts; OA, other allergies than to animal dander;
OAS, oral allergy syndrome; RH, rhinitis; tp, tree pollen; U, urticaria; ve, vegetables; wf, wheat flour.
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TABLE E2. Correlations between specific IgE levels to homolo-
gous allergens for the group of patients with dog and/or cat
allergy (n 5 24)
Can f 6 Fel d 4 Equ c 1 Can f 3 Fel d 2 Equ c 3
Can f 6 1 r 5 0.163
P > .05
r 5 0.325
P > .05
Fel d 4 1 r 5 0.557*
P < .003
Equ c 1 1
Can f 3 1 r 5 0.788*
P < .001
r 5 0.690*
P < .001
Fel d 2 1 r 5 0.684*
P < .001
Equ c 3 1
*P values less than .005 were considered highly significant.
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